cholesteryl ester transfer protein (CETP) inhibitor
Jump to navigation
Jump to search
Contraindications
- low HDL cholesterol
Mechanism of action
- lowers LDL cholesterol
- degree of LDL cholesterol lowering may not matter as much as absolute reduction in apolipoprotein B[3]
- increases HDL cholesterol
- no specific CETP inhibitor has had any beneficial effect on clinical outcomes, including death from cardiovascular event[1][2]*
* exception may be anacetrapib (not FDA-approved as of Aug 2017)
Notes
More general terms
More specific terms
Additional terms
References
- ↑ Jump up to: 1.0 1.1 Schwartz GG et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012 Nov 5 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23126252 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1206797
- ↑ Jump up to: 2.0 2.1 Keene D et al. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: Meta-analysis of randomised controlled trials including 117,411 patients. BMJ 2014 Jul 18; 349:g4379 PMID: https://www.ncbi.nlm.nih.gov/pubmed/25038074
- ↑ Jump up to: 3.0 3.1 Ference BA, Kastelein JJP, Ginsberg HN et al. Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk. JAMA 2017 Aug 28; <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28846118 <Internet> http://jamanetwork.com/journals/jama/fullarticle/2650886
Sniderman AD, Peterson ED. Genetic studies help clarify the complexities of lipid biology and treatment. JAMA 2017 Aug 28; <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28846117 <Internet> http://jamanetwork.com/journals/jama/fullarticle/2650885 - ↑ Jump up to: 4.0 4.1 Hughes S New Lipid Hypothesis Suggests CETP Inhibitors Better Without Statins. Medscape. Sep 06, 2017. Coverage from the European Society of Cardiology Congress 2017 http://www.medscape.com/viewarticle/885191